Results 191 to 200 of about 205,719 (255)

Dual pancreatic carcinomas: clonally related or independent primaries? [PDF]

NPJ Precis Oncol
Schoenfeld JD, Ravichandran V, Tarcan Z, Sahin-Ozkan H, Richards AL, Bilani N, Chou JF, O'Connor CA, McManamon D, Varghese AM, Keane F, D'Angelica MI, Jarnagin WR, Drebin J, Reidy-Lagunes D, Wei AC, Chalasani SB, Balogun F, Park W, Yu KH, Soares K, Donoghue MTA, Iacobuzio-Donahue C, Stadler ZK, Capanu M, Basturk O, O'Reilly EM.   +26 more
europepmc   +1 more source

Computational repurposing of approved drugs targeting KRAS G12D and EGFR for colorectal cancer therapy. [PDF]

PLoS One
Ibraheem W, Alsheikh F, Alzain AA, Bhongade BA, Ejaz L, Baig H, Robinson RC, El-Tanani M.   +7 more
europepmc   +1 more source

Unraveling the Impact of KRAS Accessory Proteins on Oncogenic Signaling Pathways. [PDF]

Cells
Garg V, Hofmann RNHM, Saleem M, Mirzaiebadizi A, Hashemi GS, Hameed T, Jooyeh B, Pudewell S, Mehrabipour M, Mosaddeghzadeh N, Piekorz RP, Ahmadian MR.   +11 more
europepmc   +1 more source

The Prognostic Significance of KRAS, NRAS, and BRAF Mutations in Colorectal Cancer: A Systematic Review and Meta-Analysis. [PDF]

Clin Med Insights Oncol
Oyelami M, Mgbeke O, Obadiah AA, Egbeyemi A, Marshall E.   +4 more
europepmc   +1 more source

Loss of MicroRNA-29b promotes DNMT3b-mediated STING downregulation to attenuate radiotherapy-induced antitumor immunity in KRAS-mutated colorectal cancer. [PDF]

NPJ Precis Oncol
Chang HY, Chen JY, Ke TW, Jiang YW, Hong WZ, Tsai YY, Chiang SF, Lin YS, Huang CH, Chen TH, Chao KSC, Huang KC.   +11 more
europepmc   +1 more source

Advances in targeting KRAS mutations: A promising approach for the treatment of non‑small cell lung cancer (Review). [PDF]

Oncol Rep
Sharma U, Song J, Kandu H, Zhu Y, Dai Z.
europepmc   +1 more source

Clinico-genomic characterization of RAS-mutant acute myeloid leukemia. [PDF]

Ann Hematol
Yuan R, Xie Y, Miron PM, Higgins AW, Hutchinson L, Cerny J, Patel SA.   +6 more
europepmc   +1 more source

RAF1 as a standalone therapeutic target in KRAS-driven lung adenocarcinoma: No added efficacy from co-targeting ARAF, EGFR, or DDR1. [PDF]

PLoS One
de-la-Puente-Ovejero L, Fernández-Rodríguez A, Francoz S, Aizpurua G, Lomba-Riego L, Drosten M, Guerra C, Musteanu M, Barbacid M, García-Alonso S.   +9 more
europepmc   +1 more source

Association of germline variants with KRAS-mutation status in colorectal cancer. [PDF]

Sci Rep
Tjader NP, Ramroop J, Gandhi T, Dauch C, Meadows O, Stevens P, Pearlman R, Hampel H, Aglago EK, Berndt SI, Bloomer A, Brenner H, Buchanan DD, Campbell PT, Cao Y, Chan AT, Cheng I, Dimou N, Drew DA, French AJ, Georgeson P, Giannakis M, Giles GG, Gomez M, Gruber SB, Hoffmeister M, Huang WY, Hullar MAJ, Huyghe JR, Loroña N, Moreno V, Newton CC, Nowak JA, Obón-Santacana M, Ogino S, Pellatt A, Peoples AR, Permuth JB, Schmit SL, Schoen RE, Siegel EM, Steinfelder RS, Sun W, Teer JK, Thomas CE, Trinh QM, Tsilidis K, Ugai T, Um CY, Van Guelpen B, Zaidi SH, Figueiredo J, Peters U, Phipps AI, McElroy JP, Toland AE.   +55 more
europepmc   +1 more source